To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.

NCT04542447 · clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
10
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Natureceuticals Sdn Bhd